Harwood Feffer LLP Announces Investigation of IPC The Medicines Company
NEW YORK, Feb. 12, 2014
NEW YORK, Feb. 12, 2014 /PRNewswire/ --Harwood Feffer LLP (www.hfesq.com) is
investigating potential claims against the board of directors of The Medicines
Company ("MDCO" or the "Company") (NASDAQ: MDCO), concerning whether the board
has breached its fiduciary duties to shareholders.
(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO )
On February 10, 2014 the FDA published a report stating that clinical trials
for MDCO's drug candidate, Cangrelor, had been conducted unethically and
inappropriately administered. The report stated that the unethical conduct
alone was basis for refusal of Cangrelor's new drug application.
On February 12, 2014 trading of MDCO stock was halted pending a 7:30 a.m.
meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee to
discuss the Cangrelor application.
Our investigation concerns whether the Company board of directors has breached
its fiduciary duties to shareholders, grossly mismanaged the Company, and/or
committed abuses of control in connection with the foregoing.
If you own MDCO shares and wish to discuss this matter with us, or have any
questions concerning your rights and interests with regard to this matter,
Robert I. Harwood, Esq.
Matthew M. Houston, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
Harwood Feffer has been representing individual and institutional investors
for many years, serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for
more information about the firm.
Attorney Advertising. © 2013 Harwood Feffer LLP. The law firm responsible for
this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not
guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP
Press spacebar to pause and continue. Press esc to stop.